Igm Biosciences, Inc.

Dean Ng

Ramesh Baliga

Bruce Alan Keyt

Stephen Fitzhugh Carroll

This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. The disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.

Multi-valent hepatitis B virus antigen binding molecules and uses thereof

The disclosure provides modified human IgM heavy chain constant regions that include one or more amino acid substitutions, e.g., in the C&#x3bc;3 domain, where a modified human IgM antibody comprising the modified IgM constant region and a heavy chain variable region specific for a target antigen exhibits reduced complement-dependent cytotoxicity (CDC) of cells expressing the target antigen relative to a corresponding wild-type human IgM antibody.

Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function

This disclosure provides an IgM antibody or IgM-like antibody comprising a variant J-chain and/or variant IgM heavy chain constant regions that can confer increased serum half-life upon the antibody.

Growing community of inventors

San Francisco, CA, United States of America

Dean Ng